TLR2 and glycogen storage disease VI: Apart from TLR2 neutralizing antibodies, new molecular inhibitors of TLR2 have been developed in the last years, thanks to the increasing interest on TLR2 inhibition as a potential therapeutic strategy for several non-cancerous diseases such as Parkinson’s disease and other synucleinopathies [132], renal graft dysfunction [133], and inflammatory disorders [134].